fevereiro 11, 2019

Depois 16 semanas de tratamento com dupilumab, a classificação SCORAD média diminuiu 55%.

Depois 16 weeks of dupilumab usage, patients with atopic dermatitis saw improvements in quality of life, pruritus, and sleep, de acordo com um estudo publicado em The British Journal of Dermatology.

Researchers of this prospective, observational study evaluated the efficacy of dupilumab on atopic comorbidities, symptoms, and immunoglobulin E levels in a real-life practice setting. Patients with moderate to severe atopic dermatitis completed ophthalmologic and ear nose and throat examinations, respiratory tests, SCOring Atopic Dermatitis (SCORAD) evaluations, visual analogue scales for sleep and pruritus, Avaliação Global do Investigador, Dermatology Life Quality Index, and immunoglobulin E concentration laboratory work.

Do 19 patients included, 79% were men, and the mean age was 38 anos. Follow-up data were available for 18 pacientes. At baseline, 10 patients had >2 atopic comorbidities, including asthma, allergic rhinitis, allergic conjunctivitis, or food allergy. All but 1 patient had above normal immunoglobulin E levels; 10 patients had abnormal ophthalmologic evaluations; e 15 patients had seasonal rhinitis, perennial rhinitis, or rhinosinusitis. The median SCORAD was 49, the median visual analogue scale for pruritus was 5, and the median visual analogue for sleep loss was 3.

Depois 16 semanas de tratamento com dupilumab, a classificação SCORAD média diminuiu 55% (P <.001), the median visual analogue scale for pruritus decreased significantly, the median visual analogue for sleep loss decreased significantly, and there was a significant decrease in median total immunoglobulin E levels (P =.001). Ophthalmologic examinations showed a worsening of conjunctivitis in 5 do 10 pacientes. Ear nose and throat examinations indicated 10 patients showed stability and 4 showed improvements, and no significant changes were found in asthma control.

Limitations of this study included small sample size, short-term follow-ups, and the observational nature of the study.

In conclusion, “[d]upilumab reduces global severity, pruritus, sleep loss and improves quality of life in [dermatite atópica] in real-life clinical practice.”

Divulgação: One author declared affiliation with Sanofi-Regeneron.

siga @DermAdvisor

Referência

Tauber M, Apoil PA, Richet C, et al. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice [publicado em janeiro on-line 11, 2019]. Br J Dermatol. doi: 10.1111/bjd.17629